- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: August 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in August 2027, from ClinicalTrials.gov.
Trial readouts
190 trials: 65 phase 3 (including phase 2/3) and 125 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Aug 2027 | Aveo Pharmaceuticals, INC. | Ficlatuzumab, CetuximabA Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous… | Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | NCT06064877 |
| Aug 2027 | AbbVie | VenetoclaxAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and 4 more | Phase 3 | Active not recruiting | NCT03844048 |
| Aug 2027 | AbbVie | Risankizumab, VedolizumabA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab … | Ulcerative Colitis | Phase 3 | Active not recruiting | NCT06880744 |
| Aug 2027 | Ascendis Pharma A/S | PalopegteriparatideA Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism | Hypoparathyroidism | Phase 3 | Recruiting | NCT07706764 |
| Aug 2027 | Ascentage Pharma Group International | Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine and 3 moreA Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | CLL/SLL | Phase 3 | Recruiting | NCT06319456 |
| Aug 2027 | Biohaven Pharmaceuticals | BHV-8000 10mg, BHV-8000 20 mgA Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | Parkinson Disease | Phase 2/3 | Recruiting | NCT06976268 |
| Aug 2027 | Bostal Drug Delivery Co., Ltd | Brexpiprazole for ER injection, 45 mg, Brexpiprazole for ER injection, 100 mgA Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophr… | Schizophrenia | Phase 2/3 | Not yet recruiting | NCT07742280 |
| Aug 2027 | Bostal Drug Delivery Co., Ltd | 30 mg B2227, 70 mg B2227, 150 mg B2227 and 4 moreA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participan… | Schizophrenia | Phase 2/3 | Not yet recruiting | NCT07722728 |
| Aug 2027 | Caliway Biopharmaceuticals Co., Ltd. | CBL-514 Injection, 0.9% Sodium ChlorideA Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) | Subcutaneous Fat | Phase 3 | Not yet recruiting | NCT07526974 |
| Aug 2027 | Sino Biopharmaceutical Limited | TQB2102 Injection, Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib /…A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After… | HER2 IHC3+ Advanced Colorectal Cancer | Phase 3 | Not yet recruiting | NCT07483684 |
| Aug 2027 | Crinetics Pharmaceuticals | PaltusotineCarcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Carcinoid Syndrome, Carcinoid and 7 more | Phase 3 | Active not recruiting | NCT07087054 |
| Aug 2027 | DalCor Pharmaceuticals | DalcetrapibEffect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Acute Coronary Syndrome | Phase 3 | Recruiting | NCT05918861 |
| Aug 2027 | Eli Lilly and Company | OrforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Obesity, Overweight | Phase 3 | Active not recruiting | NCT06972459 |
| Aug 2027 | Eli Lilly and Company | OrforglipronA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Obesity, Overweight and 1 more | Phase 3 | Active not recruiting | NCT06993792 |
| Aug 2027 | Eli Lilly and Company | OrforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Obesity, Overweight and 1 more | Phase 3 | Active not recruiting | NCT06972472 |
| Aug 2027 | GC Biopharma Corp | MG1111 (Barycela inj.), VARIVAX™A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months … | Varicella (Chickenpox), Chickenpox Vaccine | Phase 3 | Recruiting | NCT07054099 |
| Aug 2027 | HK inno.N Corporation | IN-B00009Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise A… | Diabetes (DM), Diabetes Mellitus Type 2 | Phase 3 | Not yet recruiting | NCT07308184 |
| Aug 2027 | Integrant Pty Ltd | Intra-Articular Injection of Growth Hormone and Platelet-R…Investigation of Growth Hormone and Platelet-Rich Plasma on Joint Health | Arthritis Ankle, Arthritis Knee | Phase 2/3 | Not yet recruiting | NCT06907121 |
| Aug 2027 | Ionis Pharmaceuticals Inc | obudanersenREVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | Angelman Syndrome | Phase 3 | Active not recruiting | NCT06914609 |
| Aug 2027 | Lipocine Inc. | LPCN 1154ABrexanolone Lifting Outcomes Of Moms | Depression, Postpartum, Postpartum Depression (PPD) and 4 more | Phase 3 | Recruiting | NCT07822321 |
| Aug 2027 | Nanjing IASO Biotechnology Co., Ltd. | Equecabtagene Autoleucel Injection, Daratumumab, Pomalidomide and 2 moreA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | Multiple Myeloma | Phase 3 | Recruiting | NCT06464991 |
| Aug 2027 | Onconic Therapeutics Inc. | JP-1366 10 mg, Lanston Capsule 15 mgStudy to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers | Peptic Ulcer | Phase 3 | Recruiting | NCT06439563 |
| Aug 2027 | Opus Genetics, Inc. | 0.75% Phentolamine Ophthalmic SolutionOPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visua… | Vision Loss Night, Vision Disorders | Phase 3 | Recruiting | NCT07140783 |
| Aug 2027 | Otsuka Pharmaceutical | EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high doseA Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 2/3 | Recruiting | NCT07086313 |
| Aug 2027 | Otsuka Pharmaceutical | EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high doseA Long-term Trial of EB-1020 in Pediatric Patients With ADHD | Attention-Deficit Hyperactivity Disorder(ADHD) | Phase 3 | Recruiting | NCT07087327 |
| Aug 2027 | Sagimet Biosciences Inc. | DenifanstatPhase 3 Study of Denifanstat in Participants With Moderate to Severe Acne | Acne Vulgaris | Phase 3 | Recruiting | NCT07863193 |
| Aug 2027 | Jiangsu Hengrui Medicine | HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets and 3 moreA Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | NCT07024173 |
| Aug 2027 | Stealth BioTherapeutics Corp | ElamipretideReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macul… | Age Related Macular Degeneration (ARMD) | Phase 3 | Active not recruiting | NCT06373731 |
| Aug 2027 | Sunshine Lake Pharma Co., Ltd. | Lerotinib, Irinotecan/TegafurStudy of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | Esophageal Cancer | Phase 3 | Recruiting | NCT04415853 |
| Aug 2027 | Travere Therapeutics, Inc. | PegtibatinasePegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment | Homocystinuria | Phase 3 | Recruiting | NCT06247085 |
| Aug 2027 | Trevi Therapeutics, Inc. | NAL ERIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | Idiopathic Pulmonary Fibrosis | Phase 3 | Recruiting | NCT07868419 |
| Aug 2027 | Ultragenyx Pharmaceutical Inc. | No Investigational Product, Adjuvant Immunomodulatory (IM) TherapyFollow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA | Mucopolysaccharidosis IIIA, MPS IIIA and 2 more | Phase 3 | Enrolling by invitation | NCT04360265 |
| Aug 2027 | Ultragenyx Pharmaceutical Inc. | Triheptanoin, MCT OilA Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Phase 3 | Active not recruiting | NCT05933200 |
| Aug 2027 | medac GmbH | MC0518, BATTreatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy | Steroid-refractory Acute Graft-versus-host Disease | Phase 3 | Recruiting | NCT04629833 |
| Aug 1, 2027 | Bluefin Biomedicine, Inc. | BFB759A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa (HS) | Phase 2/3 | Active not recruiting | NCT07287644 |
| Aug 2, 2027 | AstraZeneca | OsimertinibA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | NCT05120349 |
| Aug 4, 2027 | Pfizer | Elranatamab, LenalidomideStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | Multiple Myeloma | Phase 3 | Active not recruiting | NCT05317416 |
| Aug 5, 2027 | Johnson & Johnson | NipocalimabA Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) | Hemolytic Disease of the Fetus and Newborn | Phase 3 | Recruiting | NCT05912517 |
| Aug 6, 2027 | Nature Cell Co. Ltd. | JointStemA Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | Osteoarthritis, Knee | Phase 2/3 | Active not recruiting | NCT04368806 |
| Aug 7, 2027 | Biogen | TofersenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Develo… | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Phase 3 | Active not recruiting | NCT04856982 |
| Aug 9, 2027 | Bristol-Myers Squibb | Golcadomide, Rituximab, Cyclophosphamide and 3 moreStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated Hi… | Large B-cell Lymphoma | Phase 3 | Active not recruiting | NCT06356129 |
| Aug 10, 2027 | Novartis | BION-1301A Study of Zigakibart in Adults With IgA Nephropathy | IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | NCT05852938 |
| Aug 17, 2027 | Bristol-Myers Squibb | BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin and 1 moreA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus… | Extensive-Stage Small Cell Lung Cancer | Phase 3 | Recruiting | NCT06646276 |
| Aug 20, 2027 | Amgen | Maridebart cafraglutideMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | Obesity, Obstructive Sleep Apnea | Phase 3 | Active not recruiting | NCT07225686 |
| Aug 20, 2027 | Arrowhead Pharmaceuticals | zodasiran InjectionA Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | Homozygous Familial Hypercholesterolemia | Phase 3 | Active not recruiting | NCT07037771 |
| Aug 23, 2027 | GSK | HZ/su vaccineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | Herpes Zoster | Phase 3 | Active not recruiting | NCT05371080 |
| Aug 24, 2027 | AstraZeneca | RavulizumabEfficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | Generalized Myasthenia Gravis, gMG | Phase 3 | Recruiting | NCT07596784 |
| Aug 25, 2027 | Sanofi | PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine and 2 moreStudy of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Pneumococcal Immunization, Healthy Volunteers | Phase 3 | Active not recruiting | NCT06975878 |
| Aug 27, 2027 | GSK | BLU-5937A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension | Refractory Chronic Cough | Phase 3 | Recruiting | NCT07650084 |
| Aug 27, 2027 | Novo | EtavopivatA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | Sickle Cell Disease | Phase 3 | Recruiting | NCT06612268 |
| Aug 28, 2027 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 1, HDM1005 2A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Type 2 Diabetes | Phase 3 | Recruiting | NCT07394114 |
| Aug 30, 2027 | Amgen | Maridebart cafraglutideMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | Obstructive Sleep Apnea | Phase 3 | Active not recruiting | NCT07226765 |
| Aug 30, 2027 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 1, HDM1005 2, MazdutideA Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SG… | Type 2 Diabetes | Phase 3 | Not yet recruiting | NCT07417306 |
| Aug 30, 2027 | Insud Pharma | BenznidazoleProspective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease | Chagas Disease | Phase 3 | Active not recruiting | NCT04024163 |
| Aug 30, 2027 | Jiangsu vcare pharmaceutical technology co., LTD | VC005 low dose group, VC005 high dose groupPhase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | Phase 3 | Recruiting | NCT06723080 |
| Aug 30, 2027 | Jiangsu vcare pharmaceutical technology co., LTD | VC005 tabletsEfficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | Active Ankylosing Spondylitis | Phase 3 | Recruiting | NCT07172360 |
| Aug 30, 2027 | Sofie | [18F]FAPI-74 PET/CTUsing 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Esophageal Cancer, Gastric Cancer (GC) and 1 more | Phase 3 | Recruiting | NCT07217704 |
| Aug 31, 2027 | Compass Therapeutics, Inc. | CTX-009, PaclitaxelA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancer… | Biliary Tract Cancer, Cholangiocarcinoma and 2 more | Phase 2/3 | Active not recruiting | NCT05506943 |
| Aug 31, 2027 | Roche Holding | Obinutuzumab, Glofitamab, Rituximab and 3 moreA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Lymphoma | Phase 3 | Recruiting | NCT06084936 |
| Aug 31, 2027 | Il-Yang Pharm. Co., Ltd. | Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg CapsuleEfficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia | Benign Prostatic Hyperplasia | Phase 3 | Not yet recruiting | NCT07870759 |
| Aug 31, 2027 | Minghui Pharmaceutical (Hangzhou) Ltd | MHB018A injectionMHB018A Treatment in Patients With Chronic Thyroid Eye Disease | Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | NCT07257185 |
| Aug 31, 2027 | Mirum Pharmaceuticals | Brelovitug (BJT-778), BulevirtideStudy to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | Chronic Hepatitis D | Phase 2/3 | Recruiting | NCT07454837 |
| Aug 31, 2027 | OncoC4, Inc. | Gotistobart, DocetaxelONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | NCT05671510 |
| Aug 31, 2027 | Qilu Pharmaceutical Co., Ltd. | QL1706 injection, Vinorelbine Tartrate, Paclitaxel and 3 moreA Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Com… | Carcinoma, Non-Small-Cell Lung | Phase 3 | Recruiting | NCT05487391 |
| Aug 31, 2027 | Telix Pharmaceuticals Limited | 177Lu-TLX250Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | ccRCC, Renal Cell Carcinoma (Kidney Cancer) and 4 more | Phase 3 | Recruiting | NCT07197580 |
| Aug 2027 | Acadia Pharmaceuticals | ACP-211ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant | Phase 2 | Recruiting | NCT07284667 |
| Aug 2027 | AOBiome LLC | B244Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris | Acne Vulgaris | Phase 2 | Not yet recruiting | NCT07866105 |
| Aug 2027 | AbbVie | Telisotuzumab AdizutecanA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Me… | Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | NCT06614192 |
| Aug 2027 | Akeso | AK139A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis. | Prurigo Nodularis (PN) | Phase 2 | Not yet recruiting | NCT07883213 |
| Aug 2027 | Akeso | AK112, AK130A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer | Pancreatic Cancer | Phase 2 | Recruiting | NCT07114315 |
| Aug 2027 | Allist Pharmaceuticals, Inc. | JAB 21822A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 | Non-small Cell Lung Cancer | Phase 1/2 | Recruiting | NCT05276726 |
| Aug 2027 | Anova Innovation Limited | ANO31905, Nanoparticle Albumin-Bound Paclitaxel, GemcitabineANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Pancreatic Cancer | Phase 1/2 | Recruiting | NCT07444541 |
| Aug 2027 | Ascendis Pharma Oncology Division A/S | TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug and 4 moreA Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonis… | Advanced Solid Tumor, Locally Advanced Solid Tumor and 11 more | Phase 1/2 | Active not recruiting | NCT05081609 |
| Aug 2027 | Cellectis | UCART20x22, CLLS52Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma | B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1/2 | Recruiting | NCT05607420 |
| Aug 2027 | Sino Biopharmaceutical Limited | TQH3906 Capsule, Tofacitinib Citrate Tablet 5 mgA Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis | Psoriatic Arthritis | Phase 2 | Recruiting | NCT07406035 |
| Aug 2027 | Sino Biopharmaceutical Limited | TQB2916 Injection, ChemotherapyA Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride … | Pancreatic Cancer | Phase 2 | Recruiting | NCT06962267 |
| Aug 2027 | Climb Bio, Inc. | BudoprutugA Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia (ITP), ITP and 3 more | Phase 1/2 | Recruiting | NCT07043946 |
| Aug 2027 | Convergent Therapeutics | In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopat… and 6 moreStudy Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With… | PSMA PET-Positive Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | NCT06549465 |
| Aug 2027 | Crinetics Pharmaceuticals | CRN09682A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors and 1 more | Phase 1/2 | Active not recruiting | NCT07129252 |
| Aug 2027 | Definium Therapeutics | DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (…A Phase 2A Trial of DT402 for Autism Spectrum Disorder | Autism Spectrum Disorder, ASD | Phase 2 | Recruiting | NCT07303907 |
| Aug 2027 | Dr. Falk Pharma GmbH | ZED1227 + SIGEEvaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease | Celiac Disease | Phase 2 | Recruiting | NCT07298343 |
| Aug 2027 | Draig Therapeutics Ltd | DT-101A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Major Depressive Disorder (MDD) | Phase 2 | Recruiting | NCT07300969 |
| Aug 2027 | DualityBio Inc. | DB-1303/BNT323, Pertuzumab Injection, Ritonavir and 1 moreA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | HER2-positive Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT05150691 |
| Aug 2027 | Emmecell | 150K cells, 500K cellsStudy of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction | Corneal Edema, Fuchs and 10 more | Phase 2 | Recruiting | NCT07729137 |
| Aug 2027 | GenEditBio Limited | GEB-101 InjectionSafety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy | Hereditary Corneal Dystrophy, Corneal Abnormality and 2 more | Phase 1/2 | Not yet recruiting | NCT07750678 |
| Aug 2027 | Genfit | NTZ 500mg BID on top of SOCPhase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progress… | Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure | Phase 2 | Not yet recruiting | NCT07694297 |
| Aug 2027 | Gilead Sciences | GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet and 2 moreA Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 | HIV-1-infection | Phase 2 | Recruiting | NCT07645287 |
| Aug 2027 | Gilead Sciences | B/F/TAF, GS-3242, LenacapavirSubstudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels | HIV-1 Infection | Phase 2 | Not yet recruiting | NCT07841990 |
| Aug 2027 | Jiangsu Hengrui Medicine | SHR-1139 intravenous injection.A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Coli… | Adult Patients With Moderately to Severely Active Ulcerative Colitis | Phase 2 | Active not recruiting | NCT07232576 |
| Aug 2027 | Jiangsu Hengrui Medicine | SHR-2173 injectionPhase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2… | Primary Membranous Nephropathy | Phase 2 | Recruiting | NCT07289763 |
| Aug 2027 | Hemab ApS | HMB-001A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthen… | Glanzmann Thrombasthenia | Phase 1/2 | Active not recruiting | NCT06211634 |
| Aug 2027 | InventisBio Co., Ltd | D-2570 TabletA Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis | Psoriasis | Phase 2 | Recruiting | NCT07489885 |
| Aug 2027 | Kiora Pharmaceuticals Inc | 100 μg KIO-301, 50 μg KIO-301A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa | Retinitis Pigmentosa | Phase 2 | Recruiting | NCT06628947 |
| Aug 2027 | Korro Bio, Inc. | KRRO-121Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD | Urea Cycle Disorders, Inborn, Urea Cycle Disorders and 9 more | Phase 1/2 | Recruiting | NCT07773246 |
| Aug 2027 | Lantheus Medical Imaging | LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose …Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | Relapsed / Refractory Osteosarcoma | Phase 1/2 | Recruiting | NCT07357519 |
| Aug 2027 | Lepu Biopharma Co., Ltd. | MRG003+HX008A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT05688605 |
| Aug 2027 | Marea Therapeutics | MAR002A Study to Evaluate MAR002 for Acromegaly | Acromegaly | Phase 2 | Recruiting | NCT07641179 |
| Aug 2027 | Mediar Therapeutics | MTX-463WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | NCT06967805 |
| Aug 2027 | Molecure S.A. | OATD-01Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Phase 2 | Recruiting | NCT06205121 |
| Aug 2027 | Neuboron Bio-SciTech Co., Ltd. | Boron Neutron Capture TherapyTo Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patie… | Head and Neck Cancer | Phase 2 | Recruiting | NCT07795034 |
| Aug 2027 | Neurocrine Biosciences | NBI-1117570Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | Schizophrenia | Phase 2 | Recruiting | NCT07288333 |
| Aug 2027 | NovelMed Therapeutics | NM8074Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy | Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NCT05646524 |
| Aug 2027 | OsteoRemedies, LLC | REMEDY Spectrum IM Spacer NailStudy to Evaluate the REMEDY SPECTRUM GV IM Spacer Nail in the Treatment of Ankle-Related Infections | Periprosthetic Joint Infection | Phase 2 | Recruiting | NCT06428448 |
| Aug 2027 | Palvella Therapeutics, INC. | PTX-022A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angioker… | Angiokeratomas | Phase 2 | Recruiting | NCT07552077 |
| Aug 2027 | RDC Clinical Pty Ltd | Maca RootEffects of Macanity on Urinary Health in Males With Lower Urinary Tract Symptoms | Lower Urinary Tract Symptoms (LUTS) | Phase 2 | Not yet recruiting | NCT07816172 |
| Aug 2027 | RDC Clinical Pty Ltd | Palmitoylethanolamide (PEA)Long-Term PEA Safety Study | Healthy, Safety | Phase 2 | Active not recruiting | NCT06717867 |
| Aug 2027 | RiboX Therapeutics Ltd. | RXRG001Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1 | Radiation-Induced Xerostomia and Hyposalivation | Phase 1/2 | Recruiting | NCT06714253 |
| Aug 2027 | Ryvu Therapeutics SA | RVU120, VenetoclaxSafety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | Acute Myeloid Leukemia | Phase 2 | Recruiting | NCT06191263 |
| Aug 2027 | Seqker Biosciences, Inc. | Personalized Neoantigen Peptide VaccinePersonalized Neoantigen Peptide Vaccines for Solid Tumors | Solid Tumors, Advanced Cancer and 3 more | Phase 1/2 | Recruiting | NCT07002203 |
| Aug 2027 | Servier Bio-Innovation LLC | S095029, pembrolizumab 200 mg (KEYTRUDA ®)A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Canc… | MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer | Phase 1/2 | Active not recruiting | NCT06116136 |
| Aug 2027 | Sinfatin S.L | RimonabantEffect of Rimonabant on Hand Function in Patients With Spinal Cord Injury | Cervical Spinal Cord Injury | Phase 1/2 | Active not recruiting | NCT07843108 |
| Aug 2027 | Supernus Pharmaceuticals, INC. | SPN-817RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | Focal Onset Seizures | Phase 2 | Recruiting | NCT06798896 |
| Aug 2027 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ZG005, Gecacitinib, BevacizumabStudy of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | Cervical Cancer | Phase 1/2 | Recruiting | NCT07080216 |
| Aug 2027 | Tenaya Therapeutics, Inc. | TN-201Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associ… | Hypertrophic Cardiomyopathy | Phase 1/2 | Recruiting | NCT05836259 |
| Aug 2027 | Tortugas Neuroscience, Inc. | TRTL-913A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B) | Tinnitus | Phase 2 | Not yet recruiting | NCT07777549 |
| Aug 2027 | Triveni Bio | TRIV-573A Study Evaluating TRIV-573 in Atopic Dermatitis | Atopic Dermatitis | Phase 2 | Not yet recruiting | NCT07782333 |
| Aug 2027 | YolTech Therapeutics Co., Ltd | YOLT-203Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 1, PH1 | Phase 2 | Recruiting | NCT07587021 |
| Aug 2027 | Zai Lab (Shanghai) Co., Ltd. | ZL-1310A Study of ZL-1310 in Participants With Selected Solid Tumors | Solid Tumors | Phase 1/2 | Recruiting | NCT06885281 |
| Aug 1, 2027 | CSPC Pharmaceutical Group | SYHX2008 injection, Sandostatin LAR@A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendo… | Gastrointestinal Neuroendocrine Pancreatic Tumor | Phase 2 | Recruiting | NCT06505395 |
| Aug 1, 2027 | LaNova Medicines Limited | LM-168, ToripalimabA Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours | Advanced Solid Tumours | Phase 1/2 | Recruiting | NCT06868199 |
| Aug 1, 2027 | Lantu Biopharma | Vebeglogene autotemcelAn Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia | Beta-Thalassemia | Phase 1/2 | Active not recruiting | NCT06308159 |
| Aug 1, 2027 | SynAct Pharma Aps | AP1189, 100 mgA Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respirato… | Respiratory Viral Infection | Phase 2 | Recruiting | NCT07633288 |
| Aug 1, 2027 | Theriva Biologics, Inc. | VCN-01 oncolytic adenovirus (zabilugene almadenorepvec), Nab-paclitaxel + GemcitabineA Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV and 1 more | Phase 1/2 | Recruiting | NCT07701486 |
| Aug 1, 2027 | Triumvira Immunologics, Inc. | TAC01-CLDN18.2TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) | Metastatic Solid Tumor | Phase 1/2 | Active not recruiting | NCT05862324 |
| Aug 1, 2027 | Verastem Oncology | avutometinib + defactininb combinationContinued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | Phase 2 | Not yet recruiting | NCT07747506 |
| Aug 3, 2027 | ImmunityBio, Inc. | Nogapendekin alfa inbakicept (NAI)NAI for Sepsis With Persistent Lymphopenia | Sepsis, Septic Shock and 3 more | Phase 2 | Not yet recruiting | NCT07578558 |
| Aug 4, 2027 | AstraZeneca | AZD8421, Camizestrant, Ribociclib and 2 moreA First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Particip… | ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC) | Phase 1/2 | Recruiting | NCT06188520 |
| Aug 4, 2027 | Pfizer | PF-08653945, PF-08653944A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity | Overweight, Obesity and 6 more | Phase 2 | Active not recruiting | NCT07575932 |
| Aug 5, 2027 | Boehringer Ingelheim | BI 3802876A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohe… | Liver Cirrhosis | Phase 2 | Recruiting | NCT07325526 |
| Aug 8, 2027 | Shionogi | S-606001Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | Pompe Disease | Phase 2 | Recruiting | NCT07123155 |
| Aug 9, 2027 | Alnylam Pharmaceuticals | ALN-APPA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | Cerebral Amyloid Angiopathy | Phase 2 | Active not recruiting | NCT06393712 |
| Aug 10, 2027 | Lundbeck | Lu AG13909A Trial of Lu AG13909 in Adult Participants With Cushing's Disease | Cushing's Disease | Phase 2 | Active not recruiting | NCT06471829 |
| Aug 10, 2027 | Merck & Co. | ISL, ULO, BIC/FTC/TAFA Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type… | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Phase 2 | Active not recruiting | NCT06891066 |
| Aug 10, 2027 | Regeneron Pharmaceuticals | ALN-PNPA Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steato… | Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1/2 | Recruiting | NCT05648214 |
| Aug 11, 2027 | NGGT (Suzhou) Biotechnology Co., Ltd. | NGGT002Safety and Efficacy Study of NGGT002 in Adult Patients With Phenylketonuria | Phenylketonurias | Phase 1/2 | Recruiting | NCT06687733 |
| Aug 11, 2027 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | SSGJ-613 100 mg Q12W, SSGJ-613 200 mg Q12W, SSGJ-613 100 mg Q4W and 1 moreA Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment | Gout Arthritis | Phase 2 | Not yet recruiting | NCT07708181 |
| Aug 12, 2027 | Acrivon Therapeutics, Inc. | ACR-2316Study of ACR-2316 in Specific Advanced Solid Tumors | Specific Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06667141 |
| Aug 12, 2027 | Boehringer Ingelheim | Zongertinib, Cisplatin, Carboplatin and 2 moreBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Gi… | Lung Cancer, Non-squamous, Non-small Cell | Phase 2 | Recruiting | NCT07486817 |
| Aug 13, 2027 | DualityBio Inc. | DB-1305/BNT325, Pembrolizumab, BNT327First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Active not recruiting | NCT05438329 |
| Aug 14, 2027 | Shanghai JMT-Bio Inc. | JMT203 InjectionA Study of JMT203 in Patients With Cancer Cachexia | Non Small Cell Lung Cancer, Pancreatic Cancer and 3 more | Phase 1/2 | Recruiting | NCT06868849 |
| Aug 15, 2027 | Biomed Industries, Inc. | NA-931, Tirzepatide, NA-931 150 mg + no TirzepatideSafety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | Obesity and Overweight | Phase 2 | Not yet recruiting | NCT06732245 |
| Aug 15, 2027 | InSilico Medicine Hong Kong Limited | ISM5411 tabletsStudy Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) | Ulcerative Colitis | Phase 2 | Recruiting | NCT07265570 |
| Aug 15, 2027 | InventisBio Co., Ltd | D-2570A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis | PsA (Psoriatic Arthritis) | Phase 2 | Recruiting | NCT07315061 |
| Aug 15, 2027 | KTH Biopharma | Geniwa gelTreatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel | HPV (Human Papillomavirus)-Associated, Genital Warts | Phase 2 | Recruiting | NCT07698886 |
| Aug 15, 2027 | Novartis | YMI024Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP | Coronary Artery Disease | Phase 2 | Recruiting | NCT07830719 |
| Aug 15, 2027 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Kylo 0603 Capsule 8mg, Kylo 0603 Capsule 12mg, Kylo 0603 Capsule 16mgA Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) | Metabolic Dysfunction-Associated Steatoic Liver Disease | Phase 2 | Not yet recruiting | NCT07878091 |
| Aug 15, 2027 | Suzhou Alphamab Co., Ltd. | KN060To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients | End-Stage Renal Disease Requiring Haemodialysis | Phase 1/2 | Recruiting | NCT07201467 |
| Aug 16, 2027 | AstraZeneca | AZD0305, Elranatamab, Pomalidomide and 1 moreAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | Multiple Myeloma | Phase 1/2 | Recruiting | NCT06106945 |
| Aug 17, 2027 | Beijing Northland Biotech. Co., Ltd. | Recombinant Human Thymosin Beta 4 Injection (NL005)Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction | Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall and 3 more | Phase 2 | Not yet recruiting | NCT07586865 |
| Aug 17, 2027 | Johnson & Johnson | Amivantamab, Lazertinib, Carboplatin and 3 moreA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated No… | Carcinoma, Non-small-Cell Lung | Phase 2 | Recruiting | NCT05498428 |
| Aug 18, 2027 | Hebei Senlang Biotechnology Inc., Ltd. | CD19 CAR-T cellsAnti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases | Autoimmune Diseases | Phase 1/2 | Not yet recruiting | NCT07161193 |
| Aug 19, 2027 | Ipsen | Corabotase, DysportA Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines | Moderate to Severe Upper Facial Lines | Phase 1/2 | Active not recruiting | NCT04821089 |
| Aug 20, 2027 | Forma Therapeutics, Inc. | Etavopivat, HydroxyureaA Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell … | Sickle Cell Disease | Phase 2 | Recruiting | NCT05953584 |
| Aug 20, 2027 | LyGenesis, Inc. | LYG-LIV0001Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes | End Stage Liver Disease | Phase 2 | Recruiting | NCT04496479 |
| Aug 22, 2027 | Hangzhou PhecdaMed Co., Ltd. | TJ0113Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia | Sarcopenia | Phase 2 | Recruiting | NCT07620938 |
| Aug 23, 2027 | Novartis | RemibrutinibStudy of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) | Phase 2 | Recruiting | NCT06865651 |
| Aug 24, 2027 | Alveus Therapeutics, Inc. | ALV-100Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | Overweight , Obesity, Adults | Phase 2 | Recruiting | NCT07837973 |
| Aug 25, 2027 | Amgen | Maridebart cafraglutideA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | Overweight or Obesity and Elevated Liver Fat | Phase 2 | Active not recruiting | NCT07441252 |
| Aug 25, 2027 | Roche Holding | RO7837195A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerati… | Ulcerative Colitis | Phase 2 | Recruiting | NCT06979336 |
| Aug 26, 2027 | Johnson & Johnson | Cilta-cel, TalquetamabA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma | Multiple Myeloma | Phase 2 | Active not recruiting | NCT06550895 |
| Aug 27, 2027 | RyCarma Therapeutics, Inc. | SurlorianA Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Do… | Autosomal Dominant RYR1-Related Myopathy | Phase 2 | Recruiting | NCT07560020 |
| Aug 29, 2027 | Incyte | TafasitamabExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | Hematologic Malignancies | Phase 2 | Recruiting | NCT06465433 |
| Aug 30, 2027 | 3D Medicines (Sichuan) Co., Ltd. | EnvafolimabENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors | Solid Tumor | Phase 2 | Recruiting | NCT04891198 |
| Aug 30, 2027 | Akeso | AK146D1 for injection, AK112 Injection, Platinum chemotherapy and 1 moreA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer | Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | NCT07669779 |
| Aug 30, 2027 | Apollo Therapeutics Ltd | APL-9796A Trial of "APL-9796'' in Adults With Pulmonary Hypertension | Pulmonary Arterial Hypertension | Phase 2 | Recruiting | NCT06846554 |
| Aug 30, 2027 | Guangzhou JOYO Pharma Co., Ltd | JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical creamA Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis | Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | NCT07843290 |
| Aug 30, 2027 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | JSKN033 InjectionA Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small… | Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | NCT07283198 |
| Aug 30, 2027 | Jiangsu vcare pharmaceutical technology co., LTD | VC005 tabletsEfficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo | Non-segmental Vitiligo | Phase 2 | Recruiting | NCT07172347 |
| Aug 30, 2027 | Oncolytics Biotech | Bevacizumab, FOLFIRI, PelareorepFOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Can… | Ras-mutated Metastatic Colorectal Cancer, mCRC and 1 more | Phase 2 | Recruiting | NCT07446322 |
| Aug 30, 2027 | Plans4Care Inc | Plans4CarePlans4Care: Personalized Dementia Care on Demand | Dementia, Dementia Alzheimer Type and 2 more | Phase 2 | Not yet recruiting | NCT07115251 |
| Aug 30, 2027 | Proactive Life Inc | SleepSpaceRx CBT-I-IoT-AI, SleepEZ CBTi, Sleep Hygiene IoTDeep Sleep in Older Adults | Insomnia, Insomnia Chronic | Phase 2 | Recruiting | NCT07316153 |
| Aug 30, 2027 | Shanghai Henlius Biotech | HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric o… | Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | NCT07115485 |
| Aug 31, 2027 | Akan Biosciences, LLC | StroMelSafety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint | Osteo Arthritis Knee | Phase 1/2 | Not yet recruiting | NCT04750252 |
| Aug 31, 2027 | Alnylam Pharmaceuticals | ALN-4324A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM) | Phase 1/2 | Active not recruiting | NCT06845202 |
| Aug 31, 2027 | Ascentawits Pharmaceuticals, Ltd | AST-001A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | Solid Tumor, Pancreatic Cancer | Phase 1/2 | Recruiting | NCT06245330 |
| Aug 31, 2027 | Can Fite Biopharma | PiclidenosonAn Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome | Lowe Syndrome | Phase 2 | Not yet recruiting | NCT07410455 |
| Aug 31, 2027 | Glycyx Therapeutics | axelopran, PembolizumabA Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Phase 1/2 | Not yet recruiting | NCT07662720 |
| Aug 31, 2027 | Roche Holding | ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b and 4 moreA Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive A… | Advanced Solid Tumors, HER2-positive Breast Cancer | Phase 1/2 | Active not recruiting | NCT05593094 |
| Aug 31, 2027 | InSilico Medicine Hong Kong Limited | ISM6331Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors | Malignant Mesothelioma, Metastatic Malignant Solid Tumor and 1 more | Phase 1/2 | Recruiting | NCT06566079 |
| Aug 31, 2027 | Hansoh Pharmaceutical Group | HS-10365 capsulesA Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Phase 2 | Recruiting | NCT06147570 |
| Aug 31, 2027 | Lei Yunshang Group | Huanghou Zhixie Diwan group, Huanghou Zhixie Diwan mimicHuanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) | Patients With Irritable Bowel Syndrome With Diarrhea | Phase 2 | Not yet recruiting | NCT07721012 |
| Aug 31, 2027 | Moderna | mRNA-3927Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | Propionic Acidemia | Phase 1/2 | Recruiting | NCT04159103 |
| Aug 31, 2027 | SCAI Therapeutics | SCAI-005 0.04% 2drops TID, SCAI-005 0.08% 2drops TIDPhase 2a Study to Evaluate the Efficacy and Safety of SCAI-005 Ophthalmic Solution in Subjects With Neovascular Age-related Macular Degenera… | wetAMD, Age Related Macular Degeneration | Phase 2 | Not yet recruiting | NCT07607561 |
| Aug 31, 2027 | STCube, Inc. | Nelmastobart and DocetaxelNelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer | Non Small Cell Lung Cancer | Phase 2 | Recruiting | NCT07306624 |
| Aug 31, 2027 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium) and 1 moreTQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread | Colorectal Neoplasms | Phase 1/2 | Not yet recruiting | NCT07844187 |
| Aug 31, 2027 | Shanghai YingLi Pharmaceutical Co. Ltd. | PE0116,PE0105A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | Advanced Solid Tumors | Phase 1/2 | Not yet recruiting | NCT06026501 |
| Aug 31, 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB571 for injectionA Study of SKB571 in Participants With Gastrointestinal Tumors | Gastrointestinal Tumors | Phase 2 | Recruiting | NCT07564466 |
| Aug 31, 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Sacituzumab Tirumotecan, OsimertinibPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Gr… | Non-Small Cell Lung Cancer | Phase 2 | Recruiting | NCT07329322 |
| Aug 31, 2027 | Suzhou Sanegene Bio Inc. | SGB-9768Study of SGB-9768 in Patients With Paroxysmal Nocturnal Hemoglobinuria | PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | NCT07796256 |
| Aug 31, 2027 | Theratocular Biotek Co. | TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injectionA Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy | Geographic Atrophy Due to Age-Related Macular Degeneration | Phase 1/2 | Recruiting | NCT07668804 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.